

SAFETY DATA SHEETS

This SDS packet was issued with item:

078240162

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078848394

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

078073732



MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.

MSD Animal Health
Avenida 16 de Septiembre No. 301
Xaltocan, Xochimilco Mexico 16090 MEXICO, D.F.

MATERIAL SAFETY DATA SHEET

MSD urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

MSDS NAME: Optimmune Ophthalmic Ointment

SYNONYM(S): Optimmune Ophthalmic Ointment
None

MSDS NUMBER: SP000155

EMERGENCY NUMBER(S): (908) 423-6000 (24/7/365) English Only
Schering-Plough Security Control Center (908) 820-6921 (24 Hours)

INFORMATION: +52 (55) 57 28 44 44 (Xochimilco Mexico)

MERCK SDS HELPLINE: +1 (908) 473-3371 (Worldwide)
Monday to Friday, 9am to 5pm (US Eastern Time)

SECTION 2. HAZARDS IDENTIFICATION

EMERGENCY OVERVIEW

Colorless to light yellow
Ointment
Odor unknown
May cause cancer.
May cause effects to:
immune system
kidney
liver

EU CLASSIFICATION(S): Carc.Cat.2;R45

POTENTIAL HEALTH EFFECTS:

The toxicological properties of the mixture(s) have not been fully characterized in humans or animals. However, there are data to describe the toxicological properties of the individual ingredients. The following summary is based upon available information about the individual ingredients of the mixture(s), or of the expected properties of the mixture(s).

Cyclosporine is an immunosuppressive agent. Kidney toxicity is a critical side effect with nearly all patients that receive the drug. Long term treatment of cyclosporine can result in chronic kidney damage. Cyclosporine has been classified as a human carcinogen based on studies in humans, which indicate a causal relationship between exposure to cyclosporine and human cancer.

Effects in animal studies suggest a low order of acute toxicity. Effects seen in repeat dose studies are consistent with the pharmacological immunosuppressive activity of the drug. Kidney and liver effects have been observed at toxic dose levels.

Petrolatum may cause allergic contact dermatitis. Ingestion of petrolatum may cause laxative effects and may result in abdominal cramps and diarrhea. If aspirated, this product may cause lipid pneumonia or lipid granuloma of the lung; however, petrolatum does not present a high risk of aspiration.

LISTED CARCINOGENS

INGREDIENT	CAS NUMBER	OSHA	IARC	NTP	ACGIH
Cyclosporine	59865-13-3		1	K	

SECTION 3. COMPOSITION AND INFORMATION ON INGREDIENTS

PRODUCT USE: Veterinary product

CHEMICAL FORMULA: Mixture.

The formulations for these products are proprietary information. These formulations have the same hazardous profile; however, the presence of hazardous ingredients may vary by formulation. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 2.

CHEMICAL COMPOSITION

INGREDIENT	CAS NUMBER	EC NUMBER	EU CLASSIFICATION	PERCENT
Cyclosporine	59865-13-3			0.2
Petrolatum	8009-03-8	232-373-2	Carc.Cat.2; R45	50-60

ADDITIONAL INFORMATION: This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.

See section 15 for EU hazard classification symbols and risk and safety phrases.

SECTION 4. FIRST AID MEASURES

INHALATION: Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a physician.

SKIN CONTACT: In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.

EYE CONTACT: In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.

INGESTION: Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Center. If symptoms persist, consult a physician.

NOTE TO PHYSICIAN: This product contains cyclosporine, an immunosuppressive agent, which is known to cause cancer and kidney damage in humans.

SECTION 5. FIRE FIGHTING MEASURES

FLAMMABILITY DATA:

Flash Point: Not determined (liquids) or not applicable (solids).

SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO₂), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

SECTION 6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS:

Wear appropriate personal protective equipment as specified in Section 8. Keep personnel away from the clean-up area.

SPILL RESPONSE / CLEANUP:

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. For laboratories and small-scale operations, incidental spills within a hood or enclosure should be cleaned by using a HEPA filtered vacuum or wet cleaning methods as appropriate. For large dry or liquid spills or those spills outside enclosure or hood, appropriate emergency response personnel should be notified. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

SECTION 7. HANDLING AND STORAGE

HANDLING:

Keep containers adequately sealed during material transfer, transport, or when not in use. Wash face, hands, and any exposed skin after handling. Do not eat, drink, or smoke when using this substance or mixture.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

STORAGE:

Store in a cool, dry, well ventilated area.

See Section 8 for exposure controls and additional safe handling information.

SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION

EXPOSURE CONTROLS

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):

Respiratory Protection:	Respiratory protective equipment (RPE) may be required for certain laboratory and large-scale manufacturing tasks if potential airborne breathing zone concentrations of substances exceed the relevant exposure limit(s). Workplace risk assessment should be completed before specifying and implementing RPE usage. Potential exposure points and pathways, task duration and frequency, potential employee contact with the substance, and the ability of the substance to be rendered airborne during specific tasks should be evaluated. Initial and ongoing strategies of quantitative exposure measurement should be obtained as required by the workplace risk assessment. All RPE must conform to local and regional specifications for efficacy and performance. Consult your site or corporate health and safety professional for additional guidance.
Skin Protection:	Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
Eye Protection:	Safety glasses with side shields. Use of goggles or full face protection may be required based on hazard, potential for contact, or level of exposure. Consult your site safety staff for guidance.
Body Protection:	<p>In small-scale or laboratory operations, lab coats or equivalent protection is required. Disposable Tyvek or other dust impermeable suit should be considered based on procedure or level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.</p> <p>In large-scale or manufacturing operations, disposable Tyvek or other dust impermeable suit is recommended and based on level of exposure. Use of additional PPE such as shoe coverings, gauntlets, hood, or head covering may be necessary. Consult your site safety staff for guidance.</p>

EXPOSURE LIMIT VALUES:

No exposure limits are available for the active ingredient(s) or any other hazardous ingredient in this formulation.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

FORM: Ointment
COLOR: Colorless to light yellow
ODOR: Odor unknown
SOLUBILITY:

Water: Not determined

See Section 5 for flammability/explosivity information.

SECTION 10. STABILITY AND REACTIVITY

STABILITY/ REACTIVITY:
 Stable at ambient temperature.

INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:
 None known.

HAZARDOUS DECOMPOSITION PRODUCTS / REACTIONS:
 No dangerous decomposition if used according to manufacturer's specifications.

SECTION 11. TOXICOLOGICAL INFORMATION

The information presented below pertains to the following individual ingredients, and not to the mixture.

ACUTE TOXICITY DATA

ORAL:
 Cyclosporine: Oral LD50: 1480 mg/kg (rat)
 Toxic signs observed during the determination of the oral LD50 in rats included hyperventilation, drowsiness, muscle spasm, piloerection, weight loss and diarrhea.

DERMAL AND RESPIRATORY SENSITIZATION:
 Petrolatum was not a skin sensitizer in guinea pigs.

REPEAT DOSE TOXICITY DATA

MSDS NAME: Optimmune Ophthalmic Ointment

MSDS NUMBER: SP000155

Latest Revision Date: 21-Oct-2011

Page 4 of 6

SUBCHRONIC / CHRONIC TOXICITY:

Three month oral toxicity studies in rats and a one year oral toxicity study in dogs were conducted with cyclosporine. Rats dosed at 45 mg/kg/day and greater exhibited serious nephro- and hepatotoxicity. Immunosuppressive activity was observed in rats at 14 mg/kg/day; however, this was attributed to the pharmacological activity of the material and was not considered a toxic effect. There were no signs of toxicity observed in monkeys or dogs at doses up to 300 mg/kg/day except for a high incidence of infectious lesions in dogs which was attributed to the immunosuppressive activity of cyclosporine.

REPRODUCTIVE / DEVELOPMENTAL TOXICITY:

Two-generation reproduction and peri and postnatal development studies were conducted in rats and developmental toxicity studies were conducted in rats and rabbits with cyclosporine. No reproductive or developmental toxicity was observed at dose levels that were not maternally toxic. No effect levels were 15 mg/kg/day for reproductive effects, 17 mg/kg/day for developmental effects in rats and 30 mg/kg/day for developmental effects in rabbits.

MUTAGENICITY / GENOTOXICITY:

Cyclosporine was negative in a bacterial mutagenicity study (Ames), in mouse and Chinese hamster micronucleus assays, in a chromosome aberration assay in Chinese hamster bone marrow cells, and in a dominant lethal test in male mice. Cyclosporine and its metabolites were negative in V79 Chinese hamster fibroblasts in the HGPRT test system.

CARCINOGENICITY:

There was no evidence of carcinogenicity in rats or mice given cyclosporine at doses up to 8 or 16 mg/kg/day, respectively.

There was no evidence of carcinogenicity when petrolatum was given to mice dermally or subcutaneously or in rats intraperitoneally or orally.

SECTION 12. ECOLOGICAL INFORMATION**ECOTOXICITY DATA**

There are no ecotoxicity data available for this product or its components.

ENVIRONMENTAL DATA

There are no environmental data available for this product or its components.

SECTION 13. DISPOSAL CONSIDERATIONS**MATERIAL WASTE:**

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the recommended exposure limit(s).

PACKAGING AND CONTAINERS:

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

SECTION 14. TRANSPORT INFORMATION

This material is not subject to the transportation regulations of DOT, IATA, IMO, and the ADR.

SECTION 15. REGULATORY INFORMATION**TSCA LISTING**

INGREDIENT	TSCA
Petrolatum	X

EUROPEAN UNION REGULATIONS:

The classification presented below is based on the active ingredient(s) and individual hazardous ingredients in the product formulation.

Indication of Danger: T - Toxic.

MSDS NAME: Optimmune Ophthalmic Ointment

MSDS NUMBER: SP000155

Latest Revision Date: 21-Oct-2011

Page 5 of 6



Risk Phrases:
R45 - May cause cancer.

Safety Phrases:
S53 - Avoid exposure - obtain special instructions before use.

SECTION 16. OTHER INFORMATION

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

DEPARTMENT ISSUING MSDS:

Global Safety & the Environment
Merck & Co., Inc.
One Merck Drive
Whitehouse Station, NJ 08889

MERCK SDS HELPLINE:

+1 (908) 473-3371 (Worldwide)
Monday to Friday, 9am to 5pm (US Eastern Time)

MSDS CREATION DATE:

06-Jul-1995

SIGNIFICANT CHANGES (LAM SUBFORMAT):

New regional format, New Language (Latin-American Spanish), OEB

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

SECTION 1. IDENTIFICATION

Product name : Cyclosporine Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Carcinogenicity : Category 1B

Reproductive toxicity : Category 1B

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H350 May cause cancer.
H360Df May damage the unborn child. Suspected of damaging fertility.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Cyclosporine Formulation

Version 2.2 Revision Date: 06/12/2017 SDS Number: 608889-00004 Date of last issue: 04/28/2017
Date of first issue: 04/08/2016

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	≥ 50 - < 70
Corn oil	8001-30-7	≥ 30 - < 50
Cyclosporine	59865-13-3	≥ 0.1 - < 1

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause cancer.
May damage the unborn child. Suspected of damaging fertility.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Cyclosporine Formulation

Version 2.2 Revision Date: 06/12/2017 SDS Number: 608889-00004 Date of last issue: 04/28/2017
 Date of first issue: 04/08/2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
 Do not breathe vapors or spray mist.
 Do not swallow.
 Avoid contact with eyes.
 Handle in accordance with good industrial hygiene and safety practice.
 Keep container tightly closed.
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m ³	OSHA Z-1
		TWA (Inhalable fraction)	5 mg/m ³	ACGIH
		TWA (Mist)	5 mg/m ³	NIOSH REL
		ST (Mist)	10 mg/m ³	NIOSH REL
Corn oil	8001-30-7	TWA (mist - total)	10 mg/m ³	NIOSH REL
		TWA (mist - respirable)	5 mg/m ³	NIOSH REL
Cyclosporine	59865-13-3	TWA	25 µg/m ³ (OEB 3)	Merck
		Wipe limit	250 µg/100 cm ²	Merck

- Engineering measures : Minimize workplace exposure concentrations.
 Use with local exhaust ventilation.

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:
Safety glasses

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : viscous liquid

Color : colorless

Odor : No information available.

Odor Threshold : No data available

Cyclosporine Formulation

Version 2.2	Revision Date: 06/12/2017	SDS Number: 608889-00004	Date of last issue: 04/28/2017 Date of first issue: 04/08/2016
----------------	------------------------------	-----------------------------	---

pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
------------	---	--

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Ingredients:**Petrolatum:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from similar materials
Acute dermal toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute dermal toxicity Remarks: Based on data from similar materials

Corn oil:

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
---------------------	---	---------------------------

Cyclosporine:

Acute oral toxicity	:	LD50 (Rat): 1,480 mg/kg LD50 (Mouse): 2,329 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Acute toxicity (other routes of administration)	:	LD50 (Mouse): 107 mg/kg Application Route: Intravenous LD50 (Rat): 25.8 mg/kg Application Route: Intravenous

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Petrolatum:**

Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation
Remarks: Based on data from similar materials

Cyclosporine:

Remarks: No data available
May irritate skin.

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Petrolatum:**

Species: Rabbit
Result: No eye irritation
Method: OECD Test Guideline 405
Remarks: Based on data from similar materials

Cyclosporine:

Remarks: No data available
May irritate eyes.

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Petrolatum:**

Test Type: Buehler Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative
Remarks: Based on data from similar materials

Cyclosporine:

Remarks: May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Germ cell mutagenicity

Not classified based on available information.

Ingredients:

Petrolatum:

Genotoxicity in vitro	:	Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

Cyclosporine:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	:	Test Type: In vitro mammalian cell gene mutation test Species: Chinese hamster cells Result: negative
	:	Test Type: sister chromatid exchange assay Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: Chromosomal aberration Species: Chinese hamster Cell type: Bone marrow Result: negative
		Test Type: Chromosomal aberration Species: Mouse Result: negative

Carcinogenicity

May cause cancer.

Ingredients:

Petrolatum:

Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Cyclosporine:

Species: Mouse
Application Route: Oral
Exposure time: 78 weeks
Result: positive
Target Organs: Liver, lymphatic system

Species: Rat
Application Route: Oral
Exposure time: 2 Years
Result: positive
Target Organs: Pancreas

Species: Humans
Result: May cause cancer.
Target Organs: Immune system, Skin
Remarks: Information taken from reference works and the literature.

Carcinogenicity - Assessment : May cause cancer.

IARC

Group 1: Carcinogenic to humans

Cyclosporine 59865-13-3

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

Known to be human carcinogen

Cyclosporine 59865-13-3

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Ingredients:**Petrolatum:**

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Skin contact
Result: negative
Remarks: Based on data from similar materials

Cyclosporine:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Application Route: Oral
General Toxicity F1: LOAEL: 15 mg/kg body weight
Result: No effects on fertility., Effect on reproduction capacity.

Test Type: Fertility
Species: Rat, males
Application Route: Subcutaneous
Fertility: LOAEL: 10 mg/kg body weight
Result: Reduced fertility

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced fetal weight., Fetal mortality., Retardations., Teratogenic effects.

Test Type: Embryo-fetal development
Species: Rabbit
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced fetal weight., Fetal mortality., Retardations., Teratogenic effects.

Test Type: Development
Species: Rabbit
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Target Organs: Kidney
Result: Visceral malformations.

Test Type: Development
Species: Rat
Application Route: Intravenous
Developmental Toxicity: LOAEL: 12 mg/kg body weight
Target Organs: Heart
Result: Visceral malformations.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Ingredients:**Cyclosporine:**

Target Organs: Kidney, Liver, Immune system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Repeated dose toxicity

Ingredients:

Petrolatum:

Species: Rat
NOAEL: 5,000 mg/kg
Application Route: Ingestion
Exposure time: 2 y

Cyclosporine:

Species: Rat
NOAEL: 14 mg/kg
LOAEL: 45 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Kidney, Liver, Immune system
Symptoms: hair loss

Species: Monkey
NOAEL: 20 mg/kg
LOAEL: 60 mg/kg
Application Route: Oral
Exposure time: 13 Weeks
Target Organs: Immune system
Symptoms: Gastrointestinal disturbance, Liver disorders, Kidney disorders

Species: Dog
LOAEL: 15 mg/kg
Application Route: Oral
Exposure time: 12 Months
Target Organs: Immune system
Symptoms: Changes in the blood count, Kidney disorders, Skin disorders, hair loss

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Ingredients:

Cyclosporine:

Inhalation	:	Remarks: May cause irritation of respiratory tract.
Skin contact	:	Remarks: May irritate skin.
Eye contact	:	Symptoms: Eye irritation, eye pain
Ingestion	:	Symptoms: Kidney disorders, Tremors, hypertension, blood effects

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Ingredients:**Petrolatum:**

- Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
- Toxicity to algae : NOEL (Pseudokirchneriella subcapitata (green algae)): >= 100 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Corn oil:

- Toxicity to fish : LC0 (Danio rerio (zebra fish)): > 100 mg/l
Exposure time: 96 h
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EC0 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials
- Toxicity to algae : EL50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
Exposure time: 72 h
Remarks: Based on data from similar materials

Persistence and degradability

Ingredients:**Petrolatum:**

- Biodegradability : Result: Not readily biodegradable.
Biodegradation: 31 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Corn oil:

Biodegradability : Result: Readily biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential**Ingredients:****Corn oil:**

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Chronic Health Hazard

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Petrolatum	8009-03-8
Corn oil	8001-30-7

California Prop. 65

WARNING! This product contains a chemical known in the State of California to cause cancer.
Cyclosporine 59865-13-3

California List of Hazardous Substances

Petrolatum	8009-03-8
------------	-----------

California Permissible Exposure Limits for Chemical Contaminants

Petrolatum	8009-03-8
Corn oil	8001-30-7

The ingredients of this product are reported in the following inventories:


AICS : not determined

DSL : not determined

IECSC : not determined

Cyclosporine Formulation

Version 2.2 Revision Date: 06/12/2017 SDS Number: 608889-00004 Date of last issue: 04/28/2017
 Date of first issue: 04/08/2016

SECTION 16. OTHER INFORMATION**Further information****NFPA:****HMIS® IV:**

HEALTH	*	0
FLAMMABILITY		1
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
NIOSH REL / ST	:	STEL - 15-minute TWA exposure that should not be exceeded at any time during a workday
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable

Cyclosporine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/28/2017
2.2	06/12/2017	608889-00004	Date of first issue: 04/08/2016

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/12/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8